Rubraca® (rucaparib) tablets for Maintenance Therapy

Rubraca (pronounced roo-brah’-kah) is a prescription medicine used for:

the maintenance treatment of adults with ovarian cancer, fallopian tube, primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy

It is not known if Rubraca is safe and effective in children.

Discover how Rubraca may help maintain the response to platinum-based chemotherapy

Learn more

Hear Rita’s story about living with ovarian cancer and her experience in a Rubraca clinical trial

How to take Rubraca

Learn more

Click here if you have advanced ovarian cancer with a BRCA mutation and have finished at least 2 chemotherapy medicines.

Please note: you can rollover any word that is gold and in italics to view the definition.

INDICATIONS

What is Rubraca?

Rubraca^® (rucaparib) tablets are a prescription medicine used for:

the maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
the treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

It is not known if Rubraca is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

warning Symptoms of low blood cell counts are common during treatment with Rubraca but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca:

weakness
weight loss
fever
frequent infections

blood in urine or stool
shortness of breath
feeling very tired
bruising or bleeding more easily

warning Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

warning Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you:

warning

are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca.
- If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca.
- Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca.
- Talk to your healthcare provider about birth control methods that may be right for you.
- Tell your healthcare provider right away if you become pregnant.

warning

are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.

warning Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

warning While taking Rubraca, avoid spending time in sunlight. Rubraca can make your skin sensitive to the sun (photosensitivity). You may burn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

warning The most common side effects of Rubraca include:

nausea
tiredness or weakness
vomiting
decrease in hemoglobin (anemia)
changes in how food tastes
constipation
decrease in appetite
diarrhea

low blood cell counts
mouth sores
upper respiratory tract infection
shortness of breath
rash
changes in liver or kidney function blood tests
stomach (abdomen) pain
increased cholesterol levels

warning These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

warning You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.

INDICATIONS

What is Rubraca?

Rubraca^® (rucaparib) tablets are a prescription medicine used for:

the maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
the treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

It is not known if Rubraca is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

warning Symptoms of low blood cell counts are common during treatment with Rubraca but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca:

weakness
weight loss
fever
frequent infections

blood in urine or stool
shortness of breath
feeling very tired
bruising or bleeding more easily

warning Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

warning Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you:

warning

are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca.
- If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca.
- Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca.
- Talk to your healthcare provider about birth control methods that may be right for you.
- Tell your healthcare provider right away if you become pregnant.

warning

are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.

warning Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

warning While taking Rubraca, avoid spending time in sunlight. Rubraca can make your skin sensitive to the sun (photosensitivity). You may burn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

warning The most common side effects of Rubraca include:

nausea
tiredness or weakness
vomiting
decrease in hemoglobin (anemia)
changes in how food tastes
constipation
decrease in appetite
diarrhea

low blood cell counts
mouth sores
upper respiratory tract infection
shortness of breath
rash
changes in liver or kidney function blood tests
stomach (abdomen) pain
increased cholesterol levels

warning These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

warning You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.